Lyme Disease Vaccine Candidate: Valneva reports positive initial booster data and final Phase 1 data

Biotech company, Valneva SE, announced today positive initial booster data and final Phase 1 data for its leading, unique Lyme disease vaccine candidate VLA15. To investigate whether a VLA15 booster will elicit an anamnestic response , Valneva amended its Phase 1 study protocol during 2018, adding a booster dose in a sub-cohort of the Phase 1 study ["]

The post Lyme Disease Vaccine Candidate: Valneva reports positive initial booster data and final Phase 1 data appeared first on Outbreak News Today.